Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs 7,238
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Pipeline programs

Page 59 of 151

  1. GCT3013-03

    Genmab A/S

    Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  2. GCT3014-01

    Genmab A/S

    Relapsed or Refractory Multiple Myeloma (RRMM) Diffuse Large B Cell Lymphoma (DLBCL) Acute Myeloid Leukemia (AML)

    phase 2 small molecule active

    1 trial

  3. GDCRI/ACM/PG/PhD/10/2013-14

    BRIGHT MINDS BIOSCIENCES INC.

    Chronic Periodontitis

    phase 2 small molecule completed

    1 trial

  4. GDX012

    Takeda

    Leukemia

    phase 2 small molecule terminated

    1 trial

  5. GEICAM/2014-12

    Ningbo Cancer Hospital

    Metastatic breast cancer

    phase 2 small molecule active

    1 trial

  6. GEICAM/2020-08

    Ningbo Cancer Hospital

    Non-resectable locally advanced or metastatic HER2-positive breast cancer

    phase 2 small molecule active

    1 trial

  7. GEM 2301

    Disc Medicine

    Melanoma

    phase 2 small molecule active

    1 trial

  8. GEM 2303

    Disc Medicine

    Advanced Melanoma

    phase 2 small molecule active

    1 trial

  9. GEM-2101

    Disc Medicine

    Uveal melanoma

    phase 2 small molecule active

    1 trial

  10. GEM-PLASMACAR

    The George Institute

    Plasma cell leukaemia

    phase 2 small molecule active

    1 trial

  11. GEMCAD - 2103//MO4

    Disc Medicine

    Squamous cell carcinoma of the anal canal

    phase 2 small molecule active

    1 trial

  12. GEMCAD 2102

    Disc Medicine

    Colorectal cancer

    phase 2 small molecule active

    1 trial

  13. GEMCAD-1802

    Disc Medicine

    Colorectal cancer and metastatic disease limited to the liver with bad prognosis.

    phase 2 small molecule active

    1 trial

  14. GEMCITABINE

    Wuhan Createrna Science and Technology Co., Ltd

    Upper Tract Urothelial Carcinoma. Upper urinary tract transitional cell carcinoma

    phase 2 small molecule active

    1 trial

  15. GEN-100

    Lacuna Pharma Pty Ltd

    Acute Ischemic Stroke

    phase 2 small molecule active

    1 trial

  16. GEN1042 DP, PEMBROLIZUMAB

    Genmab A/S

    Metastatic Solid Malignant tumors

    phase 2 small molecule active

    1 trial

  17. GEN1047 DP

    Genmab A/S

    Malignant Solid Tumors

    phase 2 small molecule active

    1 trial

  18. GEN1078 DP

    Genmab A/S

    Malignant solid tumors

    phase 2 small molecule active

    1 trial

  19. GEN3014

    Genmab A/S

    Relapsed or Refractory Multiple Myeloma (RRMM)

    phase 2 mab terminated

    1 trial

  20. GGTA1 KO Thymokidney

    United Therapeutics Europe Ltd

    ESRD (End-Stage Renal Disease)

    phase 2 mab active

    1 trial

  21. GH001-TRD-201

    Elan Pharma International

    Treatment-resistant depression (TRD)

    phase 2 small molecule active

    1 trial

  22. GHB11L1

    Atea Pharmaceuticals

    Influenza, Human

    phase 2 mab completed

    1 trial

  23. GHB16L2

    Atea Pharmaceuticals

    Influenza, Human

    phase 2 mab completed

    1 trial

  24. GHR-LRX

    IONIS PHARMACEUTICALS INC

    Acromegaly

    phase 2 small molecule completed

    1 trial

  25. GI.1/GII.4 (15/15)

    Takeda

    Norovirus

    phase 2 mab completed

    1 trial

  26. GIA632

    Novartis Pharmaceuticals

    Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  27. GIM35-RIBOSIL

    Fondazione Telethon ETS

    hormone receptor positive, HER2-negative breast cancer

    phase 2 small molecule active

    1 trial

  28. GIMEMA ALL2922

    Fondazione Telethon ETS

    Adult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.

    phase 2 small molecule active

    1 trial

  29. GINECO- CE111b

    Ningbo Cancer Hospital

    Patients with a histilogically confirmed diagnosis of cervical squamous or adenosquamous carcinoma stage IB3 if N>=1 or II to IVA with any N stage according to FIGO 2018 and no evidence of metastatic disease (M0), without any prior anti-cancer treatment.

    phase 2 other active

    1 trial

  30. GINECO-EN203b

    Ningbo Cancer Hospital

    metastatic or recurrent endometrial or ovarian carcinosarcoma

    phase 2 small molecule active

    1 trial

  31. GINECO-OV243b

    Ningbo Cancer Hospital

    Patients with a confirmed diagnosis of ovarian small cell carcinoma.

    phase 2 small molecule active

    1 trial

  32. GINECO-OV244b

    Ningbo Cancer Hospital

    Platinum sensitive recurrent ovarian cancer

    phase 2 small molecule active

    1 trial

  33. GIP/GLP-1a

    United Therapeutics Europe Ltd

    Non-Alcoholic Fatty Liver Disease

    phase 2 small molecule active

    1 trial

  34. GK1-399 (formerly TTP399)

    vTv Therapeutics

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  35. GLPG0259 oral capsule

    Lakefront Biotherapeutics NV

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  36. GLPG0634

    Lakefront Biotherapeutics NV

    Crohn's Disease

    phase 2 small molecule completed

    1 trial

  37. GLPG0634

    Lakefront Biotherapeutics NV

    Rheumatoid Arthritis

    phase 2 small molecule completed

    4 trials

  38. GLPG0974

    Lakefront Biotherapeutics NV

    Ulcerative Colitis

    phase 2 small molecule completed

    1 trial

  39. GLPG1205

    Lakefront Biotherapeutics NV

    Ulcerative Colitis

    phase 2 small molecule completed

    1 trial

  40. GLPG1205

    Lakefront Biotherapeutics NV

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule completed

    1 trial

  41. GLPG1690

    Lakefront Biotherapeutics NV

    Systemic Sclerosis

    phase 2 small molecule terminated

    2 trials

  42. GLPG1690 600 mg QD

    Lakefront Biotherapeutics NV

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule completed

    1 trial

  43. GLPG1837 dose 1

    Lakefront Biotherapeutics NV

    Cystic Fibrosis

    phase 2 small molecule completed

    2 trials

  44. GLPG1972

    Lakefront Biotherapeutics NV

    Osteoarthritis

    phase 2 small molecule completed

    1 trial

  45. GLPG2222 150 mg q.d.

    Lakefront Biotherapeutics NV

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  46. GLPG2222 50 mg

    Lakefront Biotherapeutics NV

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  47. GLPG2737

    Lakefront Biotherapeutics NV

    Autosomal Dominant Polycystic Kidney Disease

    phase 2 small molecule terminated

    1 trial

  48. GLPG2737

    Lakefront Biotherapeutics NV

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.